goBalto Named Scrip Awards Finalist

Awards recognize goBalto's Select in the 'Best Technological Development in Clinical Trials - Sponsor-Focused' category

SAN FRANCISCO, September 19, 2017 -- goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, has been named a finalist in the 'Best Technological Development in Clinical Trials - Sponsor-Focused' category for the 13th Annual Scrip 2017 Awards. goBalto Select, a SaaS solution for optimizing site selection has been shortlisted for the awards ceremony and dinner, which will take place in London, United Kingdom on November 29, 2017.

The Scrip Awards have been acknowledging the hard work and innovation of pharmaceutical, biotech and supporting industries for over a decade. The awards comprise 15 categories spanning various aspects of organizational progress and innovation: from novel deals, to new drug launches and finding technological breakthroughs in clinical trials. The Scrip Awards provides the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain, and to recognize both corporate and individual achievement.

goBalto was selected as one of six finalists by an independent judging panel consisting of 16 senior industry experts.

goBalto Select delivers advanced risk-based site selection capabilities, designed to help sponsors and contract research organizations (CROs) avoid non-active and non-enrolling (NANE) sites. Sponsors and CROs often lack a transparent, evidence-based strategy for site selection. Instead, they frequently rely on archaic paper-based or spreadsheet methods to identify sites across the globe with a reasonable chance of enrolling the contracted number of subjects on schedule, and the ability to generate quality data. Clinical trials that get off to a good start are more likely to be successful trials, as research by Citeline indicates that poor site selection, the inability of sites to predict the rate of enrollment, and the subsequent need for study rescue may increase cost of trials by 20 percent or more.

"This global recognition by peers is rewarding. Our proprietary technology for site identification, feasibility assessment, and selection supports our continued efforts, and that of our customers and partners, to accelerate the clinical trials process; we are honored that our technology has been acknowledged among the best solutions in the industry," said Sujay Jadhav, goBalto's CEO.

With recent multiple enterprise expansions, goBalto now services more than two-thirds of the top 25 global pharmas and four of the top five CROs, having the largest industry-proven set of country specific regulatory business process workflows and associated in-depth activation metrics.

"Our nomination reflects goBalto's commitment to the innovation needed to mitigate risk, ensure compliance, reduce cycle times, minimize costs, and ultimately enable valuable therapies to get to patients sooner," added Jadhav.

About goBalto

goBalto is the industry leader in cloud-based study startup software for the global life sciences industry, offering the only complete end-to-end platform for starting clinical trials, from site identification, feasibility assessment and selection through to activation, with comprehensive metrics to track adherence to timelines and budget. Committed to accelerating clinical trials through innovation, product excellence, and customer success, goBalto works with four of the top five CROs and more than two-thirds of the top 25 pharmas. Our customers include: Allergan, Covance, CMIC HOLDINGS, Genentech Roche, ICON, INC Research, Novartis, and PSI CRO. goBalto is headquartered in San Francisco, with offices in Philadelphia and Singapore. For more information, visit